Ethoxysanguinarine
Based on 1 publication(s) in Google Scholar
Ethoxysanguinarine is a benzophenanthridine alkaloid natural product that is mainly found in Macleaya cordata. Ethoxysanguinarine is an inhibitor of protein phosphatase 2A (CIP2A). Ethoxysanguinarine induces cell apoptosis and inhibits colorectal cancer cells growth.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.81%
- CAS. Nr.: 28342-31-6
- Formel: C22H19NO5
- Molecular Weight:377.39
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ethoxysanguinarine
More
Biologische Aktivität
Target: CIP2A, Apoptosis[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.74 μM
Compound: ESG
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 24900782] |
| NCI-H1975 | IC50 |
1.29 μM
Compound: ESG
|
Cytotoxicity against human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 24900782] |
| NCI-H460 | IC50 |
1.56 μM
Compound: ESG
|
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 24900782] |
Ethoxysanguinarine inhibits cells vialibity with IC50 of 9.37 μM (SW480 cells); 7.19 μM (HCT116 cells); 6.55 μM (HT69 cells); 3.57 μM (SW620 cells)[1].
Ethoxysanguinarine (3 μM or 5 μM, 24 h) down-regulates phospho-Akt, decreases CIP2A/PP2A/Akt pathway expression in the SW620 and HT29 cells[1].
Ethoxysanguinarine (3 μM or 5 μM, 24 h) increases the PP2A activity and inhibits phosphorylation of CIP2A downstream molecule protein kinase B[1].
Ethoxysanguinarine (1-3 μM or 4.5-5 μM, 24 h) decreases CIP2A transcription (protein level) and induces CIP2A proteolysis in the SW620 and HT29 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Colorectal cancer (CRC) cell lines: SW620, SW480, HT29 and HCT116
-
Concentration:0.5-12 μM
-
Incubation Time:24 hours
-
Result:Inhibited the viability of CRC cells with IC50 of 3.57-9.37 μM.
-
Cell Line:Colorectal cancer (CRC) cell lines: SW620, HT29
-
Concentration:0-3 μM or 0-5 μM, respectively
-
Incubation Time:24 hours
-
Result:Induced caspase-dependent apoptosis in colorectal cancer (CRC) cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude immunodeficient mice (5-week-old, weighing about 16 g)[1]
-
Dosage:0.5 mg/kg
-
Administration:Subcutaneous injection; 5 times per week for 4 weeks
-
Result:Exhibited antitumor effects without reduce the body weight of the mice.
Chemical Information
-
CAS. Nr. 28342-31-6
-
Appearance Solid
-
Molecular Weight 377.39
-
Formel C22H19NO5
-
Color White to yellow
-
SMILES
CN1C2=C3C(C=C4OCOC4=C3)=CC=C2C5=C(C6=C(OCO6)C=C5)C1OCC
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Lett
2021 Jan 1:496:57-71. PMID: 33038488
Lösungsmittel & Löslichkeit
DMSO : 60 mg/mL (158.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.51 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6498 mL | 13.2489 mL | 26.4978 mL | 66.2445 mL |
| 5 mM | 0.5300 mL | 2.6498 mL | 5.2996 mL | 13.2489 mL | |
| 10 mM | 0.2650 mL | 1.3249 mL | 2.6498 mL | 6.6244 mL | |
| 15 mM | 0.1767 mL | 0.8833 mL | 1.7665 mL | 4.4163 mL | |
| 20 mM | 0.1325 mL | 0.6624 mL | 1.3249 mL | 3.3122 mL | |
| 25 mM | 0.1060 mL | 0.5300 mL | 1.0599 mL | 2.6498 mL | |
| 30 mM | 0.0883 mL | 0.4416 mL | 0.8833 mL | 2.2081 mL | |
| 40 mM | 0.0662 mL | 0.3312 mL | 0.6624 mL | 1.6561 mL | |
| 50 mM | 0.0530 mL | 0.2650 mL | 0.5300 mL | 1.3249 mL | |
| 60 mM | 0.0442 mL | 0.2208 mL | 0.4416 mL | 1.1041 mL | |
| 80 mM | 0.0331 mL | 0.1656 mL | 0.3312 mL | 0.8281 mL | |
| 100 mM | 0.0265 mL | 0.1325 mL | 0.2650 mL | 0.6624 mL |
Ethoxysanguinarine Related Classifications
HY-N4317 Related Classifications
Powered by Bioz